Effects of sapropterin on endothelium-dependent vasodilation in patients with CADASIL: A randomized controlled trial

Stroke

Volumn 45, Issue 10, 2014, Pages 2959-2966

  De Maria, Renata ^a   Campolo, Jonica ^a   Frontali, Marina ^b   Taroni, Franco ^c   Federico, Antonio ^d   Inzitari, Domenico ^e   Tavani, Alessandra ^f   Romano, Silvia ^g   Puca, Emanuele ^h   Orzi, Francesco ^g   Francia, Ada ^h   Mariotti, Caterina ^c   Tomasello, Chiara ^c   Dotti, Maria Teresa ^d   Stromillo, Maria Laura ^d   Pantoni, Leonardo ⁱ   Pescini, Francesca ⁱ   Valenti, Raffaella ^e   Pelucchi, Claudio ^f   Parolini, Marina ^a   Parodi, Oberdan ^a   more..

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

CADASIL; endothelium; nitric oxide; randomized controlled trial; tetrahydrobiopterin; vascular

Indexed keywords

SAPROPTERIN; BIOPTERIN;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CADASIL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HYPEREMIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL ARTERIAL TONOMETRY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; VASCULAR ENDOTHELIUM;

ADULT; AGED; BIOPTERIN; CADASIL; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPEREMIA; MALE; MIDDLE AGED; VASODILATION;

EID: 84922480870     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.005937     Document Type: Article

References (53)

1. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. 2009;8:643-653.
2. Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: A retrospective study in 411 patients. Brain. 2004;127(pt 11):2533-2539.
3. Peters N, Herzog J, Opherk C, Dichgans M. A two-year clinical followup study in 80 CADASIL subjects: progression patterns and implications for clinical trials. Stroke. 2004;35:1603-1608.
4. Sabbadini G, Francia A, Calandriello L, Di Biasi C, Trasimeni G, Gualdi GF, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). Clinical, neuroimaging, pathological and genetic study of a large Italian family. Brain. 1995;118 (pt 1):207-215.
5. Bianchi S, Scali O, Dotti MT, Pantoni L, Parnetti L, Inzitari D, et al. Gene symbol: NOTCH3. Disease: CADASIL. Hum Genet. 2005;118:534.
6. Ayata C. CADASIL: experimental insights from animal models. Stroke. 2010;41(10 suppl):S129-S134.
7. van den Boom R, Lesnik Oberstein SA, Spilt A, Behloul F, Ferrari MD, Haan J, et al. Cerebral hemodynamics and white matter hyperintensities in CADASIL. J Cereb Blood Flow Metab. 2003;23:599-604.
8. Tuominen S, Miao Q, Kurki T, Tuisku S, Pöyhönen M, Kalimo H, et al. Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients. Stroke. 2004;35:1063-1067.
9. Ruchoux MM, Chabriat H, Bousser MG, Baudrimont M, Tournier-Lasserve E. Presence of ultrastructural arterial lesions in muscle and skin vessels of patients with CADASIL. Stroke. 1994;25:2291-2292.
10. Ruchoux MM, Maurage CA. Endothelial changes in muscle and skin biopsies in patients with CADASIL. Neuropathol Appl Neurobiol. 1998;24:60-65.
11. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014;508:55-60.
12. Dziewulska D, Lewandowska E. Pericytes as a new target for pathological processes in CADASIL. Neuropathology. 2012;32:515-521.
13. Katusic ZS, Austin SA. Endothelial nitric oxide: protector of a healthy mind. Eur Heart J. 2014;35:888-894.
14. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315-424.
15. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24:413-420.
16. Moens AL, Kietadisorn R, Lin JY, Kass D. Targeting endothelial and myocardial dysfunction with tetrahydrobiopterin. J Mol Cell Cardiol. 2011;51:559-563.
17. Miller AA, Budzyn K, Sobey CG. Vascular dysfunction in cerebrovascular disease: mechanisms and therapeutic intervention. Clin Sci (Lond). 2010;119:1-17.
18. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314-1319.
19. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol (1985). 2006;101:545-548.
20. Kim JS, Lee HS, Park HY, Kim SS, Kang HG, Kim NH, et al. Endothelial function in lacunar infarction: A comparison of lacunar infarction, cerebral atherosclerosis and control group. Cerebrovasc Dis. 2009;28:166-170.
21. Chabriat H, Pappata S, Ostergaard L, Clark CA, Pachot-Clouard M, Vahedi K, et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke. 2000;31:1904-1912.
22. Pfefferkorn T, von Stuckrad-Barre S, Herzog J, Gasser T, Hamann GF, Dichgans M. Reduced cerebrovascular CO(2) reactivity in CADASIL: A transcranial Doppler sonography study. Stroke. 2001;32:17-21.
23. Rufa A, Blardi P, De Lalla A, Cevenini G, De Stefano N, Zicari E, et al. Plasma levels of asymmetric dimethylarginine in cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy. Cerebrovasc Dis. 2008;26:636-640.
24. Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L. Impaired endothelial function of forearm resistance arteries in CADASIL patients. Stroke. 2007;38:2692-2697.
25. Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M. Enhanced L-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. J Neurol. 2008;255:1203-1208.
26. Gobron C, Vahedi K, Vicaut E, Stucker O, Laemmel E, Baudry N, et al. Characteristic features of in vivo skin microvascular reactivity in CADASIL. J Cereb Blood Flow Metab. 2007;27:250-257.
27. Hamburg NM, Benjamin EJ. Assessment of endothelial function using digital pulse amplitude tonometry. Trends Cardiovasc Med. 2009;19:6-11.
28. Kuvin JT, Mammen A, Mooney P, Alsheikh-Ali AA, Karas RH. Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc Med. 2007;12:13-16.
29. Matsuzawa Y, Sugiyama S, Sumida H, Sugamura K, Nozaki T, Ohba K, et al. Peripheral endothelial function and cardiovascular events in high-risk patients. J Am Heart Assoc. 2013;25:e000426. doi: 10. 1161/ JAHA. 113. 000426.
30. Scherbakov N, Sandek A, Martens-Lobenhoffer J, Kung T, Turhan G, Liman T, et al. Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke. Cerebrovasc Dis. 2012;33:37-46.
31. Bergström A, Staalsø JM, Romner B, Olsen NV. Impaired endothelial function after aneurysmal subarachnoid haemorrhage correlates with arginine:Asymmetric dimethylarginine ratio. Br J Anaesth. 2014;112:311-318.
32. Hughes CG, Morandi A, Girard TD, Riedel B, Thompson JL, Shintani AK, et al. Association between endothelial dysfunction and acute brain dysfunction during critical illness. Anesthesiology. 2013;118:631-639.
33. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77: 1337-1344.
34. Kitano D, Chiku M, Li Y, Okumura Y, Fukamachi D, Takayama T, et al. Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia. Cardiovasc Diabetol. 2013;12:92.
35. Fujiwara Y, Mizuno T, Okuyama C, Nagakane Y, Watanabe-Hosomi A, Kondo M, et al. Simultaneous impairment of intracranial and peripheral artery vasoreactivity in CADASIL patients. Cerebrovasc Dis. 2012;33: 128-134.
36. Katusic ZS, d'Uscio LV, Nath KA. Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci. 2009;30:48-54.
37. Campolo J, De Maria R, Frontali M, Taroni F, Inzitari D, Federico A, et al. Impaired vasoreactivity in mildly disabled CADASIL patients. J Neurol Neurosurg Psychiatry. 2012;83:268-274.
38. Selamet Tierney ES, Newburger JW, Gauvreau K, Geva J, Coogan E, Colan SD, et al. Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents. J Pediatr. 2009;154:901-905.
39. Pescini F, Cesari F, Giusti B, Sarti C, Zicari E, Bianchi S, et al. Bone marrow-derived progenitor cells in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2010;41:218-223.
40. Pantoni L, Pescini F, Nannucci S, Sarti C, Bianchi S, Dotti MT, et al. Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients. Neurology. 2010;74:57-63.
41. Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart Circ Physiol. 2011;300:H1566-H1582.
42. Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain. 2004;127(pt 9):2031-2038.
43. Adib-Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke. 2010;41:630-634.
44. Porkert M, Sher S, Reddy U, Cheema F, Niessner C, Kolm P, et al. Tetrahydrobiopterin: A novel antihypertensive therapy. J Hum Hypertens. 2008;22:401-407.
45. Cosentino F, Hürlimann D, Delli Gatti C, Chenevard R, Blau N, Alp NJ, et al. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart. 2008;94:487-492.
46. Cunnington C, Van Assche T, Shirodaria C, Kylintireas I, Lindsay AC, Lee JM, et al. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation. 2012;125:1356-1366.
47. Rufa A, Dotti MT, Franchi M, Stromillo ML, Cevenini G, Bianchi S, et al. Systemic blood pressure profile in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2005;36:2554-2558.
48. Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab. 2012;302: E481-E495.
49. Charlton RA, Morris RG, Nitkunan A, Markus HS. The cognitive profiles of CADASIL and sporadic small vessel disease. Neurology. 2006;66:1523-1526.
50. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9: 689-701.
51. Kamal AK, Naqvi I, Husain MR, Khealani BA. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev. 2011;CD008076.
52. Amarenco P, Benavente O, Goldstein LB, Callahan A III, Sillesen H, Hennerici MG, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40:1405-1409.
53. SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: The SPS3 randomised trial. Lancet. 2013;382:507-515.